Cytiva, a Danaher company, has expanded its Fast Trak process development (PD) and validation services facility in Bengaluru, strengthening India’s position in the global biopharma landscape. The newly inaugurated ~30,000 sq ft centre brings upstream and downstream process development, optimisation, scale-up and validation services under one roof. The facility is designed to support multiple modalities including monoclonal antibodies (mAbs), pDNA/mRNA, recombinant proteins and viral vectors. It aims to help biopharma companies across India and Asia-Pacific shorten development timelines, reduce manufacturing risk and scale operations with greater confidence, aligning with India’s ambition to grow its bioeconomy to USD 300 billion by 2030. Pierre-Alain Ruffieux, Chief Operating Officer, Cytiva, said India’s scientific capabilities play a crucial role in global biopharma, and the expanded infrastructure will enable customers to move from concept to commercialisation with enhanced speed and reliability. Manoj Panicker, General Manager, Cytiva South Asia, noted that the facility will allow customers to innovate faster while maintaining strong process control, particularly in areas such as rare diseases, emerging modalities and the expanding biosimilars segment. According to Cytiva’s 2025 Biopharma Index, 56 per cent of global biopharma executives expect domestic biologics manufacturing to rise significantly over the next three years. This trend is particularly visible in India, where demand for biologics and biosimilars continues to grow. The centre operates in a GLP-compliant biosafety level 2 (BSL-2) environment and supports single-use bioreactor scale-up to 200 L. It can produce toxicity batch material for preclinical studies, while its ISO-certified validation laboratory offers specialised testing and documentation services for sterilising grade filters and single-use systems. By integrating sustainability best practices with comprehensive technical support, Cytiva aims to enhance yield, improve product quality, reduce manufacturing time and cost, and ensure regulatory compliance—enabling faster progress from early-stage development to commercialisation in an evolving biopharma ecosystem.